GSK PLC Reports Strong Q4 2025 Performance

Earnings and Revenue

  • Profit per share: The company reported an earnings‑per‑share figure of $0.42 for the quarter ended 31 December 2025, a rise from $0.26 a year earlier. In GBP terms, the EPS was £0.16, up from £0.10 in the corresponding period last year.
  • Revenue: Global sales reached $11.46 billion, reflecting a 10.17 % increase over the previous year’s $10.40 billion. In the UK market, revenue totaled £8.62 billion, up from £8.12 billion a year earlier.
  • Segment contribution: Sales in the specialty‑medicine division grew by 17 %, driven by strong demand for HIV and asthma products. Vaccines and respiratory medicines also contributed to the overall growth, with vaccines up 2 %.

Guidance and Strategy

  • The board reiterated its long‑term outlook, noting that cash flow and returns remain robust.
  • New chief executive Luke Miels announced plans to accelerate the development pipeline and pursue strategic acquisitions. The focus is on “product‑centric” growth, with an emphasis on convenience‑focused drugs and rapid R&D cycles.
  • Miels highlighted a target of $55 billion in sales within five years, a goal that is not linked to obesity‑related products.

Market Reaction

  • Following the earnings release, GSK shares rose 5.2 % on the London Stock Exchange, reflecting investor confidence in the company’s performance and future plans.
  • The share price, as of 04 February 2026, stood at £2.180, approaching the 52‑week high of £2.196.

Contextual Background

  • GSK is a research‑based pharmaceutical company headquartered in Brentford, United Kingdom. It operates in the Health Care sector, developing, manufacturing, and marketing vaccines, prescription and over‑the‑counter medicines, and health‑related consumer products.
  • The company’s portfolio covers infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It is listed on the London Stock Exchange and trades in GBP (GBX).

This summary reflects the latest financial disclosures and strategic announcements made by GSK PLC as of 6 February 2026.